医院急性期治疗药物监测干预的经济学评价:系统综述
多数研究聚焦成人抗菌药物TDM,14项研究认为TDM在经济和临床方面有利,但整体报告质量欠佳,CHEERS清单中位符合率为61%。
要点
- 医院TDM干预可能改善经济与临床结局,尤其针对复杂患者人群。
- 达到治疗目标可作为医院TDM干预获益的可行替代指标。
- 需系统报告经济学结局以支持投资决策。
核心结论
- TDM干预可能实现经济和临床结局的显著改善,尤其针对复杂患者人群。
- 达到治疗目标可作为医院TDM干预获益的可行替代指标。
- 需要系统报告经济学结局以支持投资决策。
研究设计与样本
- 使用CHEERS清单评估经济学分析报告质量。
主要发现
- 多数研究(n=18)聚焦成人抗菌药物TDM干预。
- 多数研究(n=13)将住院时间作为主要经济学结局。
- 14项研究认为TDM在经济和临床方面有利,4项研究报告患者亚群成本降低。
- 总体报告质量欠佳,CHEERS清单符合率中位数(范围)为61%(46-82%)。
临床怎么用
- 临床药师可参考本综述支持医院TDM项目投资论证,尤其针对复杂患者人群和抗菌药物管理。
- 可将达到治疗目标作为TDM干预获益的替代指标用于评估。
- 开展TDM经济学评价时应遵循CHEERS清单系统报告结局。
局限性
- 纳入研究总体报告质量欠佳,CHEERS清单符合率中位仅61%。
- 临床结局报告异质性大,多数研究以住院时间为主要经济学结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Therapeutic drug monitoring (TDM) aims to optimize drug therapy. As demand on health resources increases, and the technology underpinning TDM becomes more sophisticated, the economic benefits of TDM in hospitals is unclear. The aim of this systematic review was to summarize the economic evidence that could be used to support investment in TDM in hospital settings. In so doing, we sought to provide guidance for future economic evaluations. METHODS: Medline, Embase, CENTRAL, Econlit and NHS Economic Evaluation databases were searched (inception to December 2022) for economic evaluations of hospital-based TDM. Two authors reviewed the studies and extracted data. Overall quality of economic analysis reporting was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. RESULTS: Ten prospective studies (including six randomized studies) and nine retrospective studies were eligible. Overall study reporting was poor, publications meeting a median (range) of 61% (46-82%) of CHEERS checklist criteria. An antimicrobial TDM intervention for adult patients was the focus of most studies (n = 18). Variable clinical outcomes were reported, and length of stay was the primary economic outcome for most studies (n = 13). The majority of studies determined that TDM was economically and clinically favourable (n = 14), four studies reporting a cost-reduction in patient sub-populations. CONCLUSIONS: Significant improvements in both economic and clinical outcomes may be realized with TDM interventions, particularly when targeted to complex patient populations. Attainment of therapeutic target could serve as a feasible surrogate measure of benefit for hospital-based TDM interventions. However, systematic reporting of economic outcomes is needed to inform investment decisions.
引用
- Carland JE, Carland DJ, Brett J, et al. Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: A systematic review. Br J Clin Pharmacol. 2024. PMID: 38984480. doi:10.1111/bcp.16164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。